Patients with high-grade gliomas carrying IDH mutations have significantly better survival than those with wildtype IDH tumors and also respond better to treatment (Parsons et al., 2008; Yan et al., 2009; Houillier et al., 2010). The gene discussed is IDH1; the disease is central nervous system cancer.